<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166253</url>
  </required_header>
  <id_info>
    <org_study_id>919PP17</org_study_id>
    <nct_id>NCT04166253</nct_id>
  </id_info>
  <brief_title>Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin</brief_title>
  <acronym>VDDOXO</acronym>
  <official_title>The Potential Protective Effects of Vitamin (D) Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at Evaluation of the potential protective effect of Vitamin D in
      doxorubucin- induced toxicity in breast cancer patients.

      Proposal Steps:

        1. 100 Patients recruited from Alexandria Main University Hospital (AMUH), Oncology Unit
           are randomly assigned in to two groups:

             -  Control group (n=50) the patient will receive AC regimen (Doxorubucin &amp;
                cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)

             -  Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin
                D (Bon One 0.5 microgramÂ®) once daily.

        2. Echocardiography (Echo) will be done at base line and at the end of the treatment.

        3. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end
           of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Objectives: Evaluation of the potential protective effect of Vitamin D in
      doxorubucin- induced toxicity in breast cancer patients.

      Proposal Steps:

        1. Assessing breast cancer patients taking part in the study receiving adjuvant
           chemotherapy AC (Anthracycline (Doxorubucin)-cyclophosphamide) for breast cancer for 4
           cycles every 21 day (i.e. 3 months.)

        2. 100 Patients are randomly assigned in to two groups:

             -  Control group (n=50) the patient will receive AC regimen (Doxorubucin &amp;
                Cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)

             -  Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin
                D once daily.

        3. All participants are recruited from AMUH Hospital Oncology Unit. All participants will
           be given their consent. The study will be approved by research ethics committee of
           Damanhour University.

        4. Tumor staging is done according to American joint committee on cancer (TNM staging of
           breast cancer eighth edition (Amin et al., 2017).

        5. All patients will be submitted to:

             -  Full patient history and clinical examination.

             -  Routine follow up before and after each chemotherapy cycle (complete blood picture,
                liver function tests, renal function tests.

        6. Echocardiography (Echo) at base line and at the end of the treatment.

        7. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end
           of the study.

      Methodology:

      Venous blood samples will be analyzed using ELISA Vitamin D, IL-6 kits and
      immuno-histo-chemistry Troponoin-T and LDH and kits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 arms one is a control arm recieving only doxorubucin adjuvant chemotherapy and another intervention arm recieving doxorubucin as well as vitamin D orally once daily for 3 months</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant did not know the exact drug he is using.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin-T in ng/l</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Troponin-T in ng/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D in ng/ml</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Vitamin D in ng / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDH in U/L</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of LDH in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-6 in MIU/ml</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Interleukin-6 in MIU/ ml</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group of breast cancer patients will receive adjuvant AC chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Alfacalcidol oral tablets once daily</description>
    <arm_group_label>Vitamin D group</arm_group_label>
    <other_name>Alfacalcidol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients has a good performance status (ECOG 0-2) according to eastern cooperative
             oncology group (ECOG) score.

          -  Adequate complete blood picture patients.

          -  Females from (30-65) years of old.

          -  Normal renal and liver functions.

        Exclusion criteria:

          -  Cardiac diseased or reduced cardiac output with left ventricular ejection fraction
             less than 50%.

          -  Hepatic impaired patients.

          -  Pregnancy or breast feeding or child bearing state.

          -  Patient with history of allergy to vitamin D.

          -  Concomitant use of other vitamins.

          -  Renal impaired patients.

          -  History of breast cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged W Helmy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor of Pharmacology, Faculty of pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gehan A Khedr, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Oncology, Faculty of Medicine, Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noha A El Bassiouny, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Clinical Pharmacy, Faculty of Pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa A Mahmoud, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacy Specialist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa A Mahmoud, PharmD</last_name>
    <phone>+201148898967</phone>
    <email>Ironmanwolverine@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha A El Bassiouny, PhD</last_name>
    <phone>+201148898967</phone>
    <email>Noha.El.Bassiouny.85@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Damnhour university</name>
      <address>
        <city>Beheira</city>
        <zip>22511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha A El Bassiouny, PhD</last_name>
      <email>Noha.El.Bassiouny.85@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Noha El Bassiouny</investigator_full_name>
    <investigator_title>Lecturer of clinical pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Summary of data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

